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Abstract
Surveillance of Middle East respiratory syndrome coronavirus
(MERS-CoV) was conducted to explore the possible introduction
and circulation of this novel virus in Catalonia, northeastern Spain.
Five hundred and sixty-three samples from mild and severe
respiratory infections collected between January 2012 and April
2013 were screened using real-time RT-PCR. All samples were
negative, suggesting that MERS-CoV is not circulating silently in
Catalonia.
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In June 2012, a patient with a severe respiratory infection was
admitted to a hospital in Saudi Arabia. Known respiratory
pathogens were ruled out as aetiological agents of the
syndrome and the patient died of progressive respiratory
and renal failure. Respiratory samples were further analysed,
which resulted in the identification of a novel betacoronavirus:
Middle East respiratory syndrome coronavirus (MERS-CoV)
[1]. As of 12 September 2013, a total of 114 laboratory-con-
firmed cases of MERS-CoV infection, including 54 deaths, have
been reported (http://www.who.int/csr/don/2013_09_07/en/
index.html). MERS-CoV is related to bat coronaviruses [2],
although the animal reservoir has not been identified and the
virus has been only isolated in humans. The severity of the
infections and the ability of the virus to be transmitted person
to person [3,4] raised international concerns about the
possible spread and potential impact of the novel virus on
human health. Asymptomatic or mild cases of MERS-CoV have
been described [3,5], as well as cases of co-infection by
MERS-CoV with other respiratory pathogens (http://www.
who.int/csr/disease/coronavirus_infections/MERS_CoV_investi
gation_guideline_Jul13.pdf). Two recent studies assessed the
transmission potential of the virus by mathematical modelling
using currently existing data. Although the estimation of the
inter-human transmissibility suggests that the virus is currently
unlikely to cause a pandemic [6], it was also indicated that
more than half of the symptomatic human cases would remain
undetected [7].
Although most cases have been identified in Saudi Arabia,
imported cases in European countries have also been
reported. All imported cases had a travel history to the
Middle East and therefore current recommendations for
investigation of MERS-CoV cases include residence in or
history of travel to Middle Eastern countries (http://www.who.
int/csr/disease/coronavirus_infections/MERS_CoV_investigation
_guideline_Jul13.pdf). However, the fact that the virus can be
transmitted person to person and also cause mild disease
could potentially result in unnoticed importation and circula-
tion of the virus in other parts of the world apart from the
identified geographical areas. Direct traffic from the Barcelona
international airport includes 30 weekly flights to the Middle
East, accounting for more than 600 000 passengers in 2012
(http://www.bcnair-route.com/index.php/en/intercontinental-
flights). To explore whether MERS-CoV could have been
introduced into our region and be circulating at a certain level,
we screened respiratory samples from both mild and severe
cases of acute respiratory infection, independently of the travel
history of the patients.
The acute respiratory infections surveillance programme in
Catalonia, PIDIRAC (daily information system for acute
respiratory infections in Catalonia), performs surveillance
during the influenza activity season from October to May
(http://www.gencat.cat/temes/cat/salut.htm). This surveillance
system is based on 38 sentinel primary-care centres in which
physicians collect nasopharyngeal swabs from patients with
acute respiratory infections as well as 11 sentinel hospitals that
report cases of severe confirmed influenza virus infection
admitted to their facility. Samples from the primary-care
centres were screened at our laboratory for respiratory
viruses using multiplex nested RT-PCR assays [8,9] that allow
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detection of influenza viruses A, B and C, respiratory syncytial
virus, parainfluenza viruses 1–4, adenoviruses, human coro-
naviruses 229E and OC43, rhinoviruses and enteroviruses.
This surveillance network provides timely information about
the circulation of respiratory viruses in our region and carries
out virological surveillance for the European Influenza Surveil-
lance Network (EISN). For our study, we selected cases of
mild respiratory infections attending the primary-care centres
as well as patients with severe febrile respiratory syndromes
admitted to our hospital who underwent bronchoalveolar
lavage. A total of 563 samples from 563 corresponding patients
were tested, from which 195 were collected between January
2012 and June 2012 and 368 between July 2012 and April 2013.
We selected 304 nasopharyngeal swab samples from the
surveillance network that were negative for respiratory viruses
and 39 bronchoalveolar lavage samples that were negative for
standard microbiological tests. Given that co-infections with
other respiratory pathogens have been detected in patients
with MERS-CoV infection, 200 nasopharyngeal swab samples in
which a respiratory virus was identified and 20 bronchoalve-
olar lavage samples in which a respiratory pathogen was
identified were also tested. The following viruses were
detected among the positive nasopharyngeal samples: influenza
viruses (51.8%), respiratory syncytial virus (17.4%), mixed viral
infections (16.5%), adenoviruses (4.8%), coronaviruses (3.7%),
parainfluenza viruses (3.4%) and enteroviruses (2%). Among
the positive bronchoalveolar lavage samples for respiratory
pathogens, 35% were positive for bacteria, 25% were positive
for viruses, 20% were positive for fungi and 20% were mixed
infections. RNA extraction of the respiratory samples was
performed using an automated system (QiaSymphony; Qiagen,
Hilden, Germany). A recently published real-time RT-PCR
protocol for MERS-CoV [10] was implemented in our labora-
tory, and evaluated using an in vitro transcribed RNA kindly
provided by C. Drosten through the European Virus Archive
platform (http://www.european-virus-archive.com). The sensi-
tivity of the assay in our hands was similar to that described by
Corman et al. [10] (five RNA copies per reaction). In addition,
we established a generic coronavirus RT-PCR as a confirma-
tory assay [11]. This protocol further identifies the coronavirus
species by sequencing of the PCR product. This assay was
evaluated with samples containing 229E and OC43 human
coronaviruses previously detected at our laboratory [12].
All 563 respiratory samples tested were negative for the
MERS-CoV using the real-time RT-PCR protocol.
The emergence of MERS-CoV represents a public health
concern, although the virus does not seem to be as efficiently
transmissible between people as the severe acute respiratory
syndrome coronavirus. Many questions regarding the epide-
miology of the virus remain unanswered, highlighting the
importance of continued surveillance and research on
MERS-CoV. To our knowledge, this is the first exploratory
study of MERS-CoV in the general population using already
established sentinel networks. Data obtained through active
surveillance for MERS-CoV may be helpful for the global
monitoring of the virus. Moreover, our results may serve as
baseline reference data in case the virus starts to circulate in
Catalonia, northeastern Spain.
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